Functionalization with TAT-peptide enhances blood-brain barrier crossing in vitro of nanoliposomes carrying a curcumin-derivative to bind amyloid-β peptide

Journal of Nanomedicine and Nanotechnology

Volumn 4, Issue 3, 2013, Pages

  Sancini, Giulio ^a   Gregori, Maria ^a   Salvati, Elisa ^a   Cambianica, Ilaria ^a   Re, Francesca ^a   Ornaghi, Francesca ^a   Canovi, Mara ^b   Fracasso, Claudia ^b   Cagnotto, Alfredo ^b   Colombo, Miriam ^a   Zona, Cristiano ^a   Gobbi, Marco ^b   Salmona, Mario ^a   La Ferla, Barbara ^a   Nicotra, Francesco ^a   Masserini, Massimo ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Alzheimer disease (AD); Amyloid (a ); Blood brain barrier (BBB); Curcumin; Liposomes; TAT peptide

Indexed keywords

AMYLOID BETA PROTEIN; CURCUMIN; NANOLIPOSOME; NANOPARTICLE; RADIOACTIVE MATERIAL; SPHINGOMYELIN 3H; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CELL VIABILITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG STABILITY; DRUG UPTAKE; FLAME PHOTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PARENCHYMA; PROTEIN ANALYSIS; PROTEIN SYNTHESIS; PURIFICATION; RADIOACTIVITY; REVIEW; SURFACE PLASMON RESONANCE;

EID: 84878024482     PISSN: None     EISSN: 21577439     Source Type: Journal    
DOI: 10.4172/2157-7439.1000171     Document Type: Review

References (49)

1. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741-766.
2. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M (2010) Alzheimer's disease: clinical trials and drug development. Lancet Neurol 9: 702-716.
3. Hampel H, Prvulovic D, Teipel S, Jessen F, Luckhaus C, et al. (2011) The future of Alzheimer's disease: the next 10 years. Prog Neurobiol 95: 718-728.
4. Selkoe DJ (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3: 75-80.
5. Chételat G, Villemagne VL, Pike KE, Ellis KA, Ames D, et al. (2012) Relationship between memory performance and ß-amyloid deposition at different stages of Alzheimer's disease. Neurodegener Dis 10: 141-144.
6. Walsh DM, Teplow DB (2012) Alzheimer's disease and the amyloid β-protein. Prog Mol Biol Transl Sci 107: 101-124.
7. Bush AI (2002) Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging 23: 1031-1038.
8. Pollack SJ, Sadler II, Hawtin SR, Tailor VJ, Shearman MS (1995) Sulfonated dyes attenuate the toxic effects of beta-amyloid in a structure-specific fashion. Neurosci Lett 197: 211-214.
9. Sabaté R, Estelrich J (2005) Stimulatory and inhibitory effects of alkyl bromide surfactants on beta-amyloid fibrillogenesis. Langmuir 21: 6944-6949.
10. Re F, Airoldi C, Zona C, Masserini M, La Ferla B, et al. (2010) Beta amyloid aggregation inhibitors: small molecules as candidate drugs for therapy of Alzheimer's disease. Curr Med Chem 17: 2990-3006.
11. Goel A, Kunnumakkara AB, Aggarwal BB (2008) Curcumin as Curecumin: from kitchen to clinic. Biochem Pharmacol 75: 787-809.
12. Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, et al. (2008) Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 76: 1590-1611.
13. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, et al. (2000) Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 130: 467S-471S.
14. Ono K, Hasegawa K, Naiki H, Yamada M (2004) Curcumin has potent antiamyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 75: 742-750.
15. Hong HS, Rana S, Barrigan L, Shi A, Zhang Y, et al. (2009) Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo. J Neurochem 108: 1097-1108.
16. Kumaraswamy P, Sethuraman S, Krishnan UM (2013) Mechanistic Insights of Curcumin Interactions with the Core-Recognition Motif of β-Amyloid Peptide. J Agric Food Chem.
17. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ (2007) Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102: 1095-1104.
18. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, et al. (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280: 5892-5901.
19. Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, et al. (1997) Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 15: 1867-1876.
20. Sharma RA, Gescher AJ, Steward WP (2005) Curcumin: the story so far. Eur J Cancer 41: 1955-1968.
21. Ray B, Bisht S, Maitra A, Maitra A, Lahiri DK (2011) Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc™) in the neuronal cell culture and animal model: implications for Alzheimer's disease. J Alzheimers Dis 23: 61-77.
22. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF (2009) Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs 23: 35-58.
23. Craparo EF, Bondì ML, Pitarresi G, Cavallaro G (2011) Nanoparticulate systems for drug delivery and targeting to the central nervous system. CNS Neurosci Ther 17: 670-677.
24. Begley DJ (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 104: 29-45.
25. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD (2006) Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 1: 223-236.
26. Brambilla D, Le Droumaguet B, Nicolas J, Hashemi SH, Wu LP, et al. (2011) Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. Nanomedicine 7: 521-540.
27. Re F, Gregori M, Masserini M (2012) Nanotechnology for neurodegenerative disorders. Nanomedicine 8 Suppl 1: S51-S58.
28. Sahni JK, Doggui S, Ali J, Baboota S, Dao L, et al. (2011) Neurotherapeutic applications of nanoparticles in Alzheimer's disease. J Control Release 152: 208-231.
29. Roney C, Kulkarni P, Arora V, Antich P, Bonte F, et al. (2005) Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Release 108: 193-214.
30. Mourtas S, Canovi M, Zona C, Aurilia D, Niarakis A, et al. (2011) Curcumindecorated nanoliposomes with very high affinity for amyloid-β1-42 peptide. Biomaterials 32: 1635-1645.
31. Airoldi C, Zona C, Sironi E, Colombo L, Messa M, et al. (2010) Curcumin derivatives as new ligands of Aβ peptides. J Biotechnol 156: 317-324.
32. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569-1572.
33. Qin Y, Chen H, Yuan W, Kuai R, Zhang Q, et al. (2011) Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int J Pharm 419: 85-95.
34. Frankel AD, Pabo CO (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55: 1189-1193.
35. Wadia JS, Stan RV, Dowdy SF (2004) Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10: 310-315.
36. Torchilin VP, Rammohan R, Weissig V, Levchenko TS (2001) TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci U S A 98: 8786-8791.
37. Priyadarsini KI (2009) Photophysics, photochemistry and photobiology of curcumin: Studies from organic solutions, bio-mimetics and living cells. J Photoch Photobio C 10: 81-95.
38. Gobbi M, Re F, Canovi M, Beeg M, Gregori M, et al. (2010) Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. Biomaterials 31: 6519-6529.
39. Stewart JC (1980) Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 104: 10-14.
40. Re F, Cambianica I, Zona C, Sesana S, Gregori M, et al. (2011) Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. Nanomedicine 7: 551-559.
41. Le Droumaguet B, Nicolas J, Brambilla D, Mura S, Maksimenko A, et al. (2012) Versatile and efficient targeting using a single nanoparticulate platform: application to cancer and Alzheimer's disease. ACS Nano 6: 5866-5879.
42. Re F, Cambianica I, Sesana S, Salvati E, Cagnotto A, et al. (2010) Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide. J Biotechnol 156: 341-346.
43. Re F, Gregori M, Masserini M (2012) Nanotechnology for neurodegenerative disorders. Maturitas 73: 45-51.
44. Li N, Binder WH (2011) Click-chemistry for nanoparticle-modification. J Mater Chem 21: 16717-16734.
45. Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4: 145-160.
46. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD (1995) Sphingomyelincholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 72: 896-904.
47. Green M, Loewenstein PM (1988) Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55: 1179-1188.
48. Fretz MM, Storm G (2010) TAT-peptide modified liposomes: preparation, characterization, and cellular interaction. Methods Mol Biol 605: 349-359.
49. Torchilin VP (2007) Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 9: E128-147.